glp-1 eating disorder obesity drugs and disorders are not well understood yet : NPR New hope for binge eating

The GLP-1R/GcgR dual-agonist BI 456906 developed by Boehringer-Ingelheim achieves body weight reductions of 5.8% over 6 weeks and 13.8% over 16 weeks, at the maximal dosages within a multiple rising dose phase Ib clinical study [96]

Across the trials, the drugs were linked to reductions in binge eating severity, less disinhibited eating (where people struggle to resist food despite not being physically hungry), and fewer episodes of feeling out of control while eating

Amlodipine Description Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker

These changes often precede and exacerbate ALS symptoms

Define a measurable outcome: weight, waist circumference, recovery time, or cognitive test